drugset / Trial / NCT01086423

Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine

NCT01086423

Phase 3 Completed 985 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of the study is to evaluate the immunogenicity and reactogenicity of Infanrix-IPV/Hib™ vaccine when administered to healthy Chinese infants at 2, 3 and 4 or 3, 4 and 5 months of age.

Timeline

Start
2010-03-01
Primary completion
2010-11-19
Completion
2010-11-19

Drugs

EvaluationDrugModalityDoseRoute
Comparator Infanrix Hib™ Vaccine Intramuscular
Subject Infanrix-IPV+Hib™ Vaccine Intramuscular
Comparator Poliorix™ Vaccine Intramuscular